I don't know about that?
Msb only one with a chance of satisfying market.
Its only the patients who's immune system over reacts that require Stemcell Tansplant after their immune system has produced the antibodies required.
Stocking hospitals with its off the shelf stable consistant product msb has best hope of satisfying demand, imo.
Others have to prove consistancy in manufacture and have facilities approved.
Msb years ahead in my opinion.
Athersys’, Pluristem’s and Mesoblast’s mesenchymal stromal cell therapies vie for efficacy in Covid-19, page-7
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |